Nektar Therapeutics (NKTR) Receives Media Impact Rating of 0.20
News articles about Nektar Therapeutics (NASDAQ:NKTR) have trended somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a news impact score of 0.20 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.1173908335534 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- ‘Structured investment option’ is a disingenuous name for an annuity (newsok.com)
- Berko: Structured investment option and NKTR (daily-journal.com)
- BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement (feeds.reuters.com)
- Schlumberger NV (NYSE:SLB) Quarterly growth Review (fishinghd.com)
- Structured Investment Option and NKTR – Creators Syndicate (creators.com)
NKTR has been the topic of a number of recent analyst reports. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a report on Monday, August 7th. They set a “buy” rating and a $31.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. BidaskClub upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, August 18th. Finally, ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.10.
Shares of Nektar Therapeutics (NKTR) opened at 19.19 on Wednesday. The company’s 50 day moving average is $20.29 and its 200 day moving average is $18.77. The company’s market capitalization is $3.00 billion. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. During the same period last year, the business posted ($0.36) EPS. The company’s revenue was up 5.5% compared to the same quarter last year. Analysts expect that Nektar Therapeutics will post ($0.94) earnings per share for the current fiscal year.
In related news, CAO Jillian B. Thomsen sold 2,648 shares of Nektar Therapeutics stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $51,159.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Stephen K. Doberstein sold 1,701 shares of Nektar Therapeutics stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $32,863.32. Following the completion of the sale, the senior vice president now directly owns 31,102 shares of the company’s stock, valued at approximately $600,890.64. The disclosure for this sale can be found here. In the last three months, insiders sold 237,629 shares of company stock valued at $4,820,217. 5.44% of the stock is currently owned by insiders.
WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/30/nektar-therapeutics-nktr-receives-media-impact-rating-of-0-20.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.